Tyers Asset Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Tyers Asset Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-16,544	Closed	-$276K	–	1028
2018 Q3	$276K	Buy	16,544 +9,746	+143%	+$176K	0.01%	670
2018 Q2	$107K	Buy	6,798 +638	+10%	+$9.7K	﹤0.01%	825
2018 Q1	$78K	Buy	+6,160	New	+$89.1K	﹤0.01%	888

Other funds holding ALDR

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tyers Asset Management's ALDR Position: Q4 2018 in Review

Tyers Asset Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2018, closing a stake of 16,544 shares — an estimated $276K sold.

Tyers Asset Management first reported a position in ALDR in Q1 2018 and held it in 3 quarters. The position peaked at $276K in Q3 2018. 124 funds tracked by Wall St. Rank hold ALDR as of Q4 2018.

Tyers Asset Management reported no remaining Alder Biopharmaceuticals position as of Q4 2018 after selling out during the quarter.
Tyers Asset Management sold 16,544 Alder Biopharmaceuticals shares in Q4 2018, an estimated $276K.
Tyers Asset Management first reported a position in Alder Biopharmaceuticals in Q1 2018 and held it in 3 quarters.
Tyers Asset Management's Alder Biopharmaceuticals position peaked at $276K in Q3 2018.
124 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2018.

Based on Tyers Asset Management's 13F filing for Q4 2018, filed 13 Feb 2019.